Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.

As part of Y Combinator’s push into computational biology and bioinformatics, the early-stage firm is backing a team that used to work on the Human Genome Project and is now experimenting with RNA ...

Jarret Glasscock, founder and CEO, transitions to Chief Technology Officer (CTO), Board Member, and President ST. LOUIS, January 08, 2025--(BUSINESS WIRE)--Cofactor Genomics, Inc., a commercial-stage ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Cofactor AI has created software that uses artificial ...

Oxidoreductases are key enzymes in biocatalysis, but their dependence on the cofactor nicotinamide adenine dinucleotide (phosphate) (NAD(P)) presents challenges due to its high consumption and ...

Many enzymes require cofactors such as nicotinamide adenosine dinucleotide (NAD +) or nicotinamide adenosine dinucleotide phosphate (NADP +) to shuttle electrons between reactions. Artificial redox ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been ...